Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC
May 24th 2019Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.
Watch